MitoRx Therapeutics Limited Neil joins from Novo Nordisk and brings more than 20 years of experience in business development and strategic transactions Appointment strengthens MitoRx's business development capabilities as the Company advances MTRX31 towards the clinic for metabolically unhealthy obesity Harwell Oxford, UK – 3 November 2026: MitoRx Therapeutics ("MitoRx"), a biotech company targeting the restoration of healthy mitochondrial metabolism in high-risk obesity, today announces the appointment of Neil Anderson, PhD as Chief Business Officer, effective immediately. Neil will join the senior management team and report to Jon Rees, PhD, Co-founder and Chief Executive Officer.
我们公开展示核心要点。创建免费账户后可继续阅读全文、保存、讨论，并结合市场和 OSINT 背景分析。